Article Sidebar

PDF
Date Published: 24/02/2023
Abstract Views: 334
Views PDF: 183
DOI: https://doi.org/10.51298/vmj.v523i1.4402
Issue
Vol. 523 No. 1 (2023)
Section
Các bài báo
How to Cite
Lương, Đình B., Phạm , V. T. ., Bùi, T. C. ., Trần, Đình H. ., Phạm , C. P., & Mai , T. K. (2023). OVERALL SURVIVAL OUTCOME AFTER SELECTIVE INTERNAL RADIATION THERAPY WITH Y-90 RESIN MICROSPHERES FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA. Vietnam Medical Journal, 523(1). https://doi.org/10.51298/vmj.v523i1.4402

OVERALL SURVIVAL OUTCOME AFTER SELECTIVE INTERNAL RADIATION THERAPY WITH Y-90 RESIN MICROSPHERES FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA

Đình Bính Lương1,, Văn Thái Phạm 1, Tiến Công Bùi1, Đình Hà Trần1, Cẩm Phương Phạm 1, Trọng Khoa Mai 1
1 Bach Mai hospital

Main Article Content

Abstract

Aim: The study aims to evaluate the overall survival of HCC patients treated with selective internal radiation therapy (SIRT) using Y-90 resin microspheres and determine prognostic factors that impact survival at the Nuclear Medicine and Oncology Center, Bach Mai hospital. Patients: the data of the research included 111 patients who were diagnosed with HCC and had SIRT with Y-90 resin microspheres from December 2013 to June 2022. Methods: The study was designed as a retrospective investigation, uncontrolled clinical trials. Results: the median overall survival was 25,9 (15,3-36,6) months. OS ratio at 1 year was 69,7%. Factors associated with longer overall survival (OS) included ECOG 1, AFP>400ng/ml, tumor size larger than 5cm, Barcelona-Clinic Liver Cancer (BCLC) C, and portal vein thrombosis (PVT). On multivariate analysis, PVT was a predictor of longer OS. Conclusion: SIRT is an effective treatment for HCC. The lack of PVT was a positive prognostic factor for longer OS.

Article Details

Keywords

hepatocellular carcinoma, overall survival, Y-90 resin microsphere, selective internal radiation therapy

References

1. Jemal A, Ward EM, Johnson CJ, al et. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst. Published online 2017.
2. Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:541-565.
3. Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151:1155-63.e2.
4. Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287:1050-1058.
5. Nguyen Van Thai, Nguyen Tien Thinh, Thai Doan Ky, et al. Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma. BMC Gastroenterol. 2021;21: 216.
6. Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74:2342-2352.
7. Saxena A, Meteling B, Kapoor J, et al. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients. . 2014; Int J Surg. 2014;12(12):1403-1408.
8. Rognoni C, Ciani O, Sommariva S, et al. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget. 2016;7 (44):72343-72355.
9. Ozkan ZG, et al. Favorable survival time provided with radioembolization in epatocellular carcinoma patients with and without portal vein thrombosis. Cancer Biotherapy and Radiopharmaceuticals. 2015;30(3):132-138.
10. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140 (2):497-507.